A Place for Hope

For patients with BRAF-mutant melanoma, the BRAF inhibitors dabrafenib and trametinib can cause melanoma tumors to shrink rapidly, but these improvements last for about 6 months on average, after which the cancer typically begins to grow again.  Research suggests that abnormal activity in another tumor growth circuit called PI3K may help BRAF-inhibitor resistant tumors to grow.  In a trial that is unique to UCSF, we are investigating whether adding a PI3K inhibitor called "BKM120" to vemurafenib can help patients whose tumors are no longer controlled by BRAF inhibitors to go back into remission.

Basic Eligibility:

  - BRAFV600E/K mutant melanoma

  - Worsening of disease on vemurafenib

  - Patient can tolerate vemurafenib ≥ 720 mg bid

  - Any brain metastases must be stable on 2 MRI scans that are at least 4 weeks apart

Contact:  Dr. Alain Algazi, (415) 353-7552, alain.algazi@ucsf.edu

Clinicaltrials.gov link: http://www.clinicaltrials.gov/ct2/show/NCT01512251